Does Insurance Cover Wegovy? 2026 Carrier Guide

Compared to any other weight loss GLP-1, insurance coverage for Wegovy in 2026 will be wider. But the coverage depends on the plan. CVS Caremark preferred it as a GLP-1 on Aetna and other managed formularies, Cigna and UnitedHealthcare will cover it with prior authorization, Medicare will cover it for weight loss starting July 1, 2026, through the GLP-1 Bridge pilot, and TRICARE will cover it with BMI-based prior authorization, as will about 13 state Medicaid programs. For covered, a BMI of 30 or higher (or ≥ 27 if there is a weight related medical condition).

This hub shows you every single card, the universal criteria, costs in each scenario and the deep guide for your particular card. 

Wegovy Coverage by Carrier: The 2026 Map

Deep guides per carrier: Aetna, UnitedHealthcare, Cigna, Blue Cross, BCBS, Medicare, Wegovy and Medicare how-to, and TRICARE.

The Three Advantages That Make Wegovy the Covered GLP-1

The first step to getting preferred-formulary status was to receive it. According to Healthcare Dive, CVS Caremark's July 2025 agreement with Novo Nordisk results in Wegovy becoming the only weight-loss GLP-1 available on standard formularies for approximately a third of commercial members, while other authorizations should automatically switch to Wegovy. Other PBMs will typically use Wegovy first step therapy even if both medications are prescribed.

The cardiovascular indication was second. The FDA has recently approved the decreased risk of heart attack, stroke and cardiovascular death in adults with known heart disease and obesity or overweight, marking a new pathway for treating the disease, which today excludes weight loss.

The Bridge is Medicare's pilot. As of July 1, 2026, Medicare coverage for Wegovy for weight management will be in place until December 2027, and the $245 federal price will have a $50 cap per month for copay, according to NPR, so long as someone has a BMI of 27 or above with a qualifying condition and joins Medicare during their Part D enrollment period.

Universal Criteria Where Coverage Exists

Clinical bar is the same across carriers and is based on the FDA label: BMI of 30 or higher, or 27 or higher and at least one weight-related condition (hypertension, prediabetes, dyslipidemia, or sleep apnea). Most plans have a requirement that documented participation in the lifestyle program is at least 3-6 months, a baseline weight is recorded on file, and renewal with at least 5 percent weight loss from baseline.

Timelines are determined by the submission discipline. Whole files are completed (BMI history, COMBO history, program notes) in 72 hours or less, missing pieces cause denial-resubmit loops that turn into months. Schedule the authorization expiration for the day of approval and record all of the weigh-ins in your chart to renew. 

What Wegovy Costs in Every Scenario

By plan design, covered commercial copays are $25 to $200 per month; the new flat-$200 weight-management structures are starting to emerge in 2026 in Caremark, Cigna, and various Blues. The money-saving card from Novo Nordisk reduces eligible commercial copay up to $100 per month and is compatible with most designs. Members of high deductibles pay negotiated rates ($650-$900) until their deductibles are met.

Medicare pathways are subject to the monthly limit of $50. In states that cover Medicaid, members are charged $0 to $8. At no coverage, NovoCare Pharmacy and big-brand retailers offer Wegovy for about $499/month — the federal TrumpRx channel has semaglutide running about $350 as it slowly rolls out until 2026 — and the $1350 list price is only to be avoided.

When You're Denied: The Escalation Playbook

This denial letter will include the name of your play. Employer who never purchased this weight-management benefit: go to HR with $200 copay structures (which limit employer cost); explore the cardiovascular option if the employer has a history of cardiovascular disease; or go with self-pay in between. Clinical denial: correct the identified documentation deficit and resubmit, the quickest to win in the system. Step Therapy / quantity: prescriber records the clinical indications / requests an override.

The formal ladder is behind it all – internal appeal decided within 30 days (72 hours expedited) followed by federally guaranteed external review by an independent physician. These are winnable with objective criteria and whole game are complete BMI and program documentation.